Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Viatris Inc
(NQ:
VTRS
)
10.92
-0.15 (-1.36%)
Streaming Delayed Price
Updated: 12:48 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viatris Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
October 21, 2022
Upgrades
Via
Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
October 14, 2022
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.
Via
Benzinga
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
October 03, 2022
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.
Via
Benzinga
Viatris: Q2 Earnings Insights
August 08, 2022
Viatris (NASDAQ:VTRS) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings for Viatris
May 10, 2022
Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:
Via
Benzinga
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus
May 09, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 22, 2022
On Thursday, 1076 companies hit new 52-week lows.
Via
Benzinga
Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs
September 22, 2022
The decision affects two of Merck's best-selling drugs.
Via
Investor's Business Daily
Recent Stock Purchase September 2022
September 19, 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines.
Via
Talk Markets
Recap: Viatris Q1 Earnings
May 09, 2022
Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label
April 13, 2022
Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 20, 2022
On Tuesday, 507 stocks hit new 52-week lows.
Via
Benzinga
7 Screaming Buy Stock Picks to Beat the September Market Slump
September 13, 2022
Savvy investors can use these stock picks to beat the market and take advantage of market weakness and panic selling.
Via
InvestorPlace
September 2022 Stock Considerations
September 08, 2022
Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Monday
September 19, 2022
On Monday, 429 stocks made new 52-week lows.
Via
Benzinga
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
September 03, 2022
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,...
Via
MarketBeat
Stocks That Hit 52-Week Lows On Thursday
September 01, 2022
On Thursday, 529 companies set new 52-week lows.
Via
Benzinga
This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems
August 24, 2022
From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle.
Via
Benzinga
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
August 03, 2022
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
7 High-Quality Dividend Stocks With High Yields
June 07, 2022
These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments.
Via
InvestorPlace
Looking Into Viatris's Return On Capital Employed
June 03, 2022
According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4.
Via
Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
May 31, 2022
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood...
Via
FinancialNewsMedia
Current Report: Viatris
May 20, 2022
Viatris Inc’s price per share was $11.68 as of yesterday's market close. One year ago its price was $15.59.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
May 10, 2022
Upgrades
Via
Benzinga
3 Top S&P 500 Stock Market Gainers Today
May 09, 2022
Hard-hit stocks led S&P 500 winners. Commodity stocks were the big losers.
Via
Investor's Business Daily
27 Recession-Resistant Stocks To Look At Now
May 09, 2022
When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not...
Via
Benzinga
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Pfizer: What Comes After the Covid-19 Fire?
April 21, 2022
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.